Assessing agreement between different polygenic risk scores in the UK Biobank

(Supplementary Tables and Figure)

Lei Clifton1, Jennifer A Collister1, Xiaonan Liu1, Tom J Littlejohn1, David J Hunter1,2

Affiliate Institutions:

1. Nuffield Department of Population Health, University of Oxford, UK.

2. Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, USA

Corresponding Author: Lei Clifton, lei.clifton@ndph.ox.ac.uk

# Table of SNP QC

Supplementary Table 1: SNP QC

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Disease | PRS | nSNPs | Unavailable in UKB | Ambiguous | Imputation info < 0.4 | MAF < 0.005 | Remaining SNPs |
| Breast cancer | A | 313 | 7 | 0 | 0 | 1 | 305 |
| B | 118,388 | 0 | 43 | 107 | 2938 | 115,300 |
| Hypertension | A | 267 | 0 | 0 | 0 | 3 | 264 |
| B | 884 | 0 | 3 | 0 | 0 | 881 |
| Dementia | A | 20 | 0 | 0 | 0 | 0 | 20 |
| B | 39 | 0 | 0 | 0 | 1 | 38 |

# Tables for top 1% risk

Supplementary Table 2: Cross-classification of predicted risk of hypertension, according to the percentiles of each PRS. Number of participants are shown as n (col%, row%, cell%). Higher percentiles of PRS indicate increased risk of hypertension; “≥ 99%” percentile corresponds to the top 1% risk.

| Percentiles of PRS A | Percentiles of PRS B |
| --- | --- |
| < 1% | 1-20% | 20-40% | 40-60% | 60-80% | 80-99% | ≥ 99% |
| < 1% | 758 (23.9,23.9, 0.2) | 2024 (63.7, 3.4, 0.6) | 298 (9.4, 0.5, 0.1) | 78 (2.5, 0.1, 0.0) | 16 (0.5, 0.0, 0.0) | 2 (0.1, 0.0, 0.0) | 0 (0.0, 0.0, 0.0) |
| 1-20% | 2043 (3.4, 64.3, 0.6) | 29305 (48.6, 48.6, 9.2) | 15985 (26.5, 25.2, 5.0) | 8431 (14.0, 13.3, 2.7) | 3653 (6.1, 5.8, 1.2) | 923 (1.5, 1.5, 0.3) | 1 (0.0, 0.0,0.0) |
| 20-40% | 290 (0.5, 9.1, 0.1) | 16014 (25.2, 26.5, 5.0) | 18776 (29.6, 29.6, 5.9) | 14854 (23.4, 23.4, 4.7) | 9954 (15.7, 15.7, 3.1) | 3617 (5.7, 6.0, 1.1) | 11 (0.0, 0.3, 0.0) |
| 40-60% | 68 (0.1, 2.1, 0.0) | 8391 (13.2, 13.9, 2.6) | 14996 (23.6,23.6, 4.7) | 16595 (26.1, 26.1, 5.2) | 15006 (23.6, 23.6, 4.7) | 8381 (13.2, 13.9, 2.6) | 79 (0.1, 2.5, 0.0) |
| 60-80% | 14 (0.0, 0.4, 0.0) | 3664 (5.8, 6.1, 1.2) | 9803 (15.4, 15.4, 3.1) | 14988 (23.6, 23.6, 4.7) | 18520 (29.2,29.2, 5.8) | 16226 (25.5, 26.9, 5.1) | 301 (0.5, 9.5,0.1) |
| 80-99% | 3 (0.0, 0.1, 0.0) | 940 (1.6, 1.6, 0.3) | 3650 (6.0, 5.7, 1.1) | 8495 (14.1, 13.4, 2.7) | 16055 (26.6, 25.3, 5.1) | 29140 (48.3, 48.3, 9.2) | 2057 (3.4, 64.8, 0.6) |
| ≥ 99% | 0 (0.0, 0.0, 0.0) | 3 (0.1, 0.0, 0.0) | 10 (0.3,0.0, 0.0) | 74 (2.3, 0.1, 0.0) | 311 (9.8, 0.5, 0.1) | 2051 (64.6, 3.4, 0.6) | 727 (22.9, 22.9, 0.2) |

Supplementary Table 3: Cross-classification of predicted risk of dementia, according to the percentiles of each PRS. Number of participants are shown as n (col%, row%, cell%). Higher percentiles of PRS indicate increased risk of dementia; “≥ 99%” percentile corresponds to the top 1% risk.

| Percentiles of PRS A | Percentiles of PRS B |
| --- | --- |
| < 1% | 1-20% | 20-40% | 40-60% | 60-80% | 80-99% | ≥ 99% |
| < 1% | 1137 (32.1, 33.9, 0.3) | 2224 (62.8, 3.5, 0.7) | 133 (3.8, 0.2,0.0) | 34 (1.0, 0.1, 0.0) | 9 (0.3, 0.0, 0.0) | 2 (0.1, 0.0, 0.0) | 0 (0.0, 0.0, 0.0) |
| 1-20% | 2044 (3.2, 60.9, 0.6) | 35338 (55.4, 55.4, 10.5) | 16481 (25.8, 24.5, 4.9) | 6688 (10.5, 10.0, 2.0) | 2514 (3.9, 3.7, 0.7) | 690 (1.1, 1.1, 0.2) | 7 (0.0, 0.2, 0.0) |
| 20-40% | 146 (0.2, 4.3, 0.0) | 16919 (25.2, 26.5, 5.0) | 22481 (33.5, 33.5, 6.7) | 16239 (24.2, 24.2, 4.8) | 8415 (12.6, 12.5, 2.5) | 2793 (4.2, 4.4, 0.8) | 38 (0.1, 1.1, 0.0) |
| 40-60% | 28 (0.0, 0.8, 0.0) | 6806 (10.1, 10.7, 2.0) | 16940 (25.2, 25.2, 5.0) | 20053 (29.9, 29.9, 6.0) | 15928 (23.7, 23.7, 4.7) | 7242 (10.8, 11.4, 2.2) | 130 (0.2, 3.9, 0.0) |
| 60-80% | 2 (0.0, 0.1, 0.0) | 2129 (3.2, 3.3, 0.6) | 8760 (13.1, 13.0, 2.6) | 17008 (25.3, 25.3, 5.1) | 22453 (33.5, 33.4, 6.7) | 16323 (24.3, 25.6, 4.9) | 424 (0.6, 12.6, 0.1) |
| 80-99% | 0 (0.0, 0.0, 0.0) | 365 (0.6, 0.6, 0.1) | 2336 (3.7, 3.5, 0.7) | 7089 (11.1, 10.6, 2.1) | 17630 (27.6, 26.3, 5.3) | 34362 (53.9, 53.9, 10.2) | 1994 (3.1, 59.4, 0.6) |
| ≥ 99% | 0 (0.0, 0.0, 0.0) | 0 (0.0, 0.0, 0.0) | 8 (0.2, 0.0, 0.0) | 25 (0.7, 0.0, 0.0) | 189 (5.6, 0.3, 0.1) | 2370 (70.6, 3.7, 0.7) | 763 (22.7, 22.7, 0.2) |

Supplementary Table 4: Cross-classification of predicted risk of breast cancer among participants who experienced the outcome, according to the percentiles of each PRS. Initial score is [PRS-A](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323553/), updated score is [PRS-B](https://www.sciencedirect.com/science/article/pii/S0002929720303207?via%3Dihub). 6,347 of 171,490 individuals (3.7%) experienced the outcome. Row %s shown, and may not add up to 100 due to rounding. Categorical NRI (95% CI): 0.013 (-0.007, 0.033).

| Percentiles of PRS A | Percentiles of PRS B | % reclassified |
| --- | --- | --- |
| < 1% | 1-20% | 20-40% | 40-60% | 60-80% | 80-99% | ≥ 99% |
| < 1% | 4 (16.0) | 17 (68.0) | 2 (8.0) | 2 (8.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 84.0% |
| 1-20% | 8 (1.3) | 217 (36.5) | 186 (31.3) | 106 (17.8) | 62 (10.4) | 16 (2.7) | 0 (0.0) | 63.5% |
| 20-40% | 1 (0.1) | 173 (20.2) | 222 (25.9) | 222 (25.9) | 169 (19.7) | 71 (8.3) | 0 (0.0) | 74.1% |
| 40-60% | 1 (0.1) | 96 (8.4) | 221(19.4) | 310 (27.3) | 288 (25.3) | 219 (19.3) | 2 (0.2) | 72.7% |
| 60-80% | 0 (0.0) | 56 (3.7) | 192 (12.8) | 278 (18.5) | 445 (29.7) | 511 (34.1) | 18 (1.2) | 70.3% |
| 80-99% | 0 (0.0) | 17 (0.8) | 80 (3.9) | 235 (11.4) | 459 (22.3) | 1132 (55.1) | 131 (6.4) | 44.9% |
| ≥ 99% | 0 (0.0) | 1 (0.6) | 0 (0.0) | 2 (1.1) | 10 (5.6) | 111 (62.4) | 54 (30.3) | 69.7% |

Supplementary Table 5: Cross-classification of predicted risk of hypertension among participants who experienced the outcome, according to the percentiles of each PRS. Initial score is [PRS-A](https://www.nature.com/articles/ng.3768), updated score is [PRS-B](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284793/). 137,649 of 317,581 individuals (43.3%) experienced the outcome. Row %s shown, and may not add up to 100 due to rounding. Categorical NRI (95% CI): 0.061 (0.056, 0.067).

| Percentilesof PRS A | Percentiles of PRS B | % reclassified |
| --- | --- | --- |
| < 1% | 1-20% | 20-40% | 40-60% | 60-80% | 80-99% | ≥ 99% |
| < 1% | 179 (20.4) | 564 (64.3) | 100 (11.4) | 27 (3.1) | 6 (0.7) | 1 (0.1) | 0 (0.0) | 79.6% |
| 1-20% | 496 (2.3) | 9456 (43.5) | 6083 (28.0) | 3556 (16.4) | 1689 (7.8) | 458 (2.1) | 1 (0.0) | 56.5% |
| 20-40% | 71 (0.3) | 5399 (21.3) | 7224 (28.4) | 6230 (24.5) | 4570 (18.0) | 1895 (7.5) | 5 (0.0) | 71.6% |
| 40-60% | 15 (0.1) | 2972 (10.7) | 6049 (21.8) | 7245 (26.1) | 7109 (25.6) | 4305 (15.5) | 45 (0.2) | 73.9% |
| 60-80% | 3 (0.0) | 1292 (4.4) | 3913 (13.4) | 6541 (22.3) | 8917 (30.5) | 8445 (28.8) | 170 (0.6) | 69.5% |
| 80-99% | 2 (0.0) | 355 (1.2) | 1490 (4.8) | 3885 (12.6) | 7883 (25.6) | 15959 (51.8) | 1251 (4.1) | 48.2% |
| ≥ 99% | 0 (0.0) | 1 (0.1) | 6 (0.3) | 38 (2.1) | 142 (7.9) | 1161 (64.8) | 445 (24.8) | 75.2% |

Supplementary Table 6: Cross-classification of predicted risk of dementia among participants who experienced the outcome, according to the percentiles of each PRS. Initial score is [PRS-A](https://doi.org/10.1038/s41467-020-18534-1), updated score is [PRS-B](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438688/). 4,460 of 335,689 individuals (1.3%) experienced the outcome. Row %s shown, and may not add up to 100 due to rounding. Categorical NRI (95% CI): 0.031 (0.008, 0.054).

| Percentilesof PRS A | Percentiles of PRS B | % reclassified |
| --- | --- | --- |
| < 1% | 1-20% | 20-40% | 40-60% | 60-80% | 80-99% | ≥ 99% |
| < 1% | 6 (17.6) | 24 (70.6) | 3 (8.8) | 1 (2.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 82.4% |
| 1-20% | 22 (3.3) | 333 (49.9) | 170 (25.4) | 96 (14.4) | 31 (4.6) | 16 (2.4) | 0 (0.0) | 50.1% |
| 20-40% | 1 (0.1) | 160 (20.7) | 267 (34.5) | 196 (25.4) | 107 (13.8) | 40 (5.2) | 2 (0.3) | 65.5% |
| 40-60% | 0 (0.0) | 73 (8.4) | 238 (27.2) | 241 (27.6) | 222 (25.4) | 97 (11.1) | 3 (0.3) | 72.4% |
| 60-80% | 0 (0.0) | 24 (2.5) | 96 (9.9) | 209 (21.6) | 328 (33.9) | 301 (31.1) | 10 (1.0) | 66.1% |
| 80-99% | 0 (0.0) | 6 (0.6) | 25 (2.3) | 105 (9.8) | 259 (24.3) | 615 (57.6) | 58 (5.4) | 42.4% |
| ≥ 99% | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (2.7) | 53 (70.7) | 20 (26.7) | 73.3% |

#

# Tables for top 5% risk

Supplementary Table 7: Cross-classification of predicted risk of breast cancer, according to the percentiles of each PRS. Number of participants are shown as n (col%, row%, cell%). Higher percentiles of PRS indicate increased risk of breast cancer; “≥ 99%” percentile corresponds to the top 1% risk.

| Percentiles of PRS A | Percentiles of PRS B |
| --- | --- |
| < 5% | 5-20% | 20-40% | 40-60% | 60-80% | 80-95% | ≥ 95% |
| < 5% | 2901 (33.8, 33.8, 1.7) | 3319 (38.7, 12.9, 1.9) | 1588 (18.5, 4.6, 0.9) | 582 (6.8, 1.7, 0.3) | 161 (1.9, 0.5, 0.1) | 24 (0.3, 0.1, 0.0) | 1 (0.0, 0.0, 0.0) |
| 5-20% | 3302 (12.8, 38.5, 1.9) | 8489 (33.0, 33.0, 5.0) | 7406 (28.8, 21.6, 4.3) | 4158 (16.2, 12.1, 2.4) | 1900 (7.4, 5.5, 1.1) | 451 (1.8, 1.8, 0.3) | 16 (0.1, 0.2, 0.0) |
| 20-40% | 1569 (4.6, 18.3, 0.9) | 7417 (21.6, 28.8, 4.3) | 9989 (29.1, 29.1, 5.8) | 8053 (23.5, 23.5, 4.7) | 5210 (15.2, 15.2, 3.0) | 1877 (5.5, 7.3, 1.1) | 183 (0.5, 2.1, 0.1) |
| 40-60% | 603 (1.8, 7.0, 0.4) | 4088 (11.9, 15.9, 2.4) | 7998 (23.3, 23.3, 4.7) | 8908 (26.0, 26.0, 5.2) | 8050 (23.5, 23.5, 4.7) | 4144 (12.1, 16.1, 2.4) | 507 (1.5, 5.9, 0.3) |
| 60-80% | 171 (0.5, 2.0, 0.1) | 1938 (5.7, 7.5, 1.1) | 5296 (15.4, 15.4, 3.1) | 7988 (23.3, 23.3, 4.7) | 10047 (29.3, 29.3, 5.9) | 7400 (21.6, 28.8, 4.3) | 1458 (4.3, 17.0, 0.9) |
| 80-95% | 29 (0.1, 0.3, 0.0) | 453 (1.8, 1.8, 0.3) | 1869 (7.3, 5.4, 1.1) | 4070 (15.8, 11.9, 2.4) | 7402 (28.8, 21.6, 4.3) | 8554 (33.3, 33.3, 5.0) | 3346 (13.0, 39.0, 2.0) |
| ≥ 95% | 0 (0.0, 0.0, 0.0) | 19 (0.2, 0.1, 0.0) | 152 (1.8, 0.4, 0.1) | 539 (6.3, 1.6, 0.3) | 1528 (17.8, 4.5, 0.9) | 3273 (38.2, 12.7, 1.9) | 3064 (35.7, 35.7, 1.8) |

Supplementary Table 8: Cross-classification of predicted risk of hypertension, according to the percentiles of each PRS. Number of participants are shown as n (col%, row%, cell%). Higher percentiles of PRS indicate increased risk of hypertension; “≥ 99%” percentile corresponds to the top 1% risk.

| Percentilesof PRS A | Percentiles of PRS B |
| --- | --- |
| < 5% | 5-20% | 20-40% | 40-60% | 60-80% | 80-95% | ≥ 95% |
| < 5% | 5721 (36.0, 36.0, 1.8) | 6110 (38.5, 12.8, 1.9) | 2784 (17.5, 4.4, 0.9) | 940 (5.9, 1.5, 0.3) | 281 (1.8, 0.4, 0.1) | 42 (0.3, 0.1, 0.0) | 2 (0.0, 0.0, 0.0) |
| 5-20% | 6156 (12.9, 38.8, 1.9) | 16143 (33.9, 33.9, 5.1) | 13499 (28.3, 21.3, 4.3) | 7569 (15.9, 11.9, 2.4) | 3388 (7.1, 5.3, 1.1) | 830 (1.7, 1.7, 0.3) | 52 (0.1, 0.3, 0.0) |
| 20-40% | 2772 (4.4, 17.5, 0.9) | 13532 (21.3, 28.4, 4.3) | 18776 (29.6, 29.6, 5.9) | 14854 (23.4, 23.4, 4.7) | 9954 (15.7, 15.7, 3.1) | 3375 (5.3, 7.1, 1.1) | 253 (0.4, 1.6, 0.1) |
| 40-60% | 943 (1.5, 5.9, 0.3) | 7516 (11.8, 15.8, 2.4) | 14996 (23.6, 23.6, 4.7) | 16595 (26.1, 26.1, 5.2) | 15006 (23.6, 23.6, 4.7) | 7475 (11.8, 15.7, 2.4) | 985 (1.6, 6.2, 0.3) |
| 60-80% | 248 (0.4, 1.6, 0.1) | 3430 (5.4, 7.2, 1.1) | 9803 (15.4, 15.4, 3.1) | 14988 (23.6, 23.6, 4.7) | 18520 (29.2, 29.2, 5.8) | 13721 (21.6, 28.8, 4.3) | 2806 (4.4, 17.7, 0.9) |
| 80-95% | 40 (0.1, 0.3, 0.0) | 839 (1.8, 1.8, 0.3) | 3390 (7.1, 5.3, 1.1) | 7640 (16.0, 12.0, 2.4) | 13584 (28.5, 21.4, 4.3) | 16051 (33.7, 33.7, 5.1) | 6093 (12.8, 38.4, 1.9) |
| ≥ 95% | 0 (0.0, 0.0, 0.0) | 67 (0.4, 0.1, 0.0) | 270 (1.7, 0.4, 0.1) | 929 (5.9, 1.5, 0.3) | 2782 (17.5, 4.4, 0.9) | 6143 (38.7, 12.9, 1.9) | 5688 (35.8, 35.8, 1.8) |

Supplementary Table 9: Cross-classification of predicted risk of dementia, according to the percentiles of each PRS. Number of participants are shown as n (col%, row%, cell%). Higher percentiles of PRS indicate increased risk of dementia; “≥ 99%” percentile corresponds to the top 1% risk.

| Percentilesof PRS A | Percentiles of PRS B |
| --- | --- |
| < 5% | 5-20% | 20-40% | 40-60% | 60-80% | 80-95% | ≥ 95% |
| < 5% | 7715 (44.8, 46.0, 2.3) | 6662 (38.7, 13.2, 2.0) | 2073 (12.0, 3.1, 0.6) | 552 (3.2, 0.8, 0.2) | 186 (1.1, 0.3, 0.1) | 38 (0.2, 0.1, 0.0) | 1 (0.0, 0.0, 0.0) |
| 5-20% | 6431 (12.8, 38.3, 1.9) | 19935 (39.8, 39.6, 5.9) | 14541 (29.0, 21.7, 4.3) | 6170 (12.3, 9.2, 1.8) | 2337 (4.7, 3.5, 0.7) | 595 (1.2, 1.2, 0.2) | 65 (0.1, 0.4, 0.0) |
| 20-40% | 2044 (3.0, 12.2, 0.6) | 15021 (22.4, 29.8, 4.5) | 22481 (33.5, 33.5, 6.7) | 16239 (24.2, 24.2, 4.8) | 8415 (12.6, 12.5, 2.5) | 2509 (3.7, 5.0, 0.7) | 322 (0.5, 1.9, 0.1) |
| 40-60% | 493 (0.7, 2.9, 0.1) | 6341 (9.4, 12.6, 1.9) | 16940 (25.2, 25.2, 5.0) | 20053 (29.9, 29.9, 6.0) | 15928 (23.7, 23.7, 4.7) | 6412 (9.6, 12.7, 1.9) | 960 (1.4, 5.7, 0.3) |
| 60-80% | 95 (0.1, 0.6, 0.0) | 2036 (3.0, 4.0, 0.6) | 8760 (13.1, 13.0, 2.6) | 17008 (25.3, 25.3, 5.1) | 22453 (33.5, 33.4, 6.7) | 14144 (21.1, 28.1, 4.2) | 2603 (3.9, 15.5, 0.8) |
| 80-95% | 7 (0.0, 0.0, 0.0) | 348 (0.7, 0.7, 0.1) | 2223 (4.4, 3.3, 0.7) | 6570 (13.0, 9.8, 2.0) | 15502 (30.8, 23.1, 4.6) | 19584 (38.9, 38.9, 5.8) | 6113 (12.1, 36.4, 1.8) |
| ≥ 95% | 0 (0.0, 0.0, 0.0) | 10 (0.1, 0.0, 0.0) | 121 (0.7, 0.2, 0.0) | 544 (3.2, 0.8, 0.2) | 2317 (13.8, 3.5, 0.7) | 7071 (42.1, 14.0, 2.1) | 6721 (40.0, 40.0, 2.0) |

Supplementary Table 10: Cross-classification of predicted risk of breast cancer among participants who experienced the outcome, according to the percentiles of each PRS. Initial score is [PRS-A](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323553/), updated score is PRS-B. 6,347 of 171,490 individuals (3.7%) experienced the outcome. Row %s shown, and may not add up to 100 due to rounding. Categorical NRI (95% CI): 0.011 (-0.009, 0.032).

| Percentilesof PRS A | Percentiles of PRS B | % reclassified |
| --- | --- | --- |
| < 5% | 5-20% | 20-40% | 40-60% | 60-80% | 80-95% | ≥ 95% |
| < 5% | 31 (29.0) | 41 (38.3) | 23 (21.5) | 10 (9.3) | 2 (1.9) | 0 (0.0) | 0 (0.0) | 71.0% |
| 5-20% | 30 (5.8) | 144 (28.1) | 165 (32.2) | 98 (19.1) | 60 (11.7) | 16 (3.1) | 0 (0.0) | 71.9% |
| 20-40% | 16 (1.9) | 158 (18.4) | 222 (25.9) | 222 (25.9) | 169 (19.7) | 66 (7.7) | 5 (0.6) | 74.1% |
| 40-60% | 12 (1.1) | 85 (7.5) | 221 (19.4) | 310 (27.3) | 288 (25.3) | 188 (16.5) | 33 (2.9) | 72.7% |
| 60-80% | 3 (0.2) | 53 (3.5) | 192 (12.8) | 278 (18.5) | 445 (29.7) | 426 (28.4) | 103 (6.9) | 70.3% |
| 80-95% | 1 (0.1) | 15 (1.0) | 74 (4.9) | 213 (14.0) | 383 (25.2) | 568 (37.3) | 267 (17.6) | 62.7% |
| ≥ 95% | 0 (0.0) | 2 (0.3) | 6 (0.8) | 24 (3.4) | 86 (12.1) | 257 (36.1) | 336 (47.3) | 52.7% |

Supplementary Table 11: Cross-classification of predicted risk of hypertension among participants who experienced the outcome, according to the percentiles of each PRS. Initial score is [PRS-A](https://www.nature.com/articles/ng.3768), updated score is [PRS-B](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284793/). 137,649 of 317,581 individuals (43.3%) experienced the outcome. Row %s shown, and may not add up to 100 due to rounding. Categorical NRI (95% CI): 0.064 (0.059, 0.07).

| Percentilesof PRS A | Percentiles of PRS B | % reclassified |
| --- | --- | --- |
| < 5% | 5-20% | 20-40% | 40-60% | 60-80% | 80-95% | ≥ 95% |
| < 5% | 1509 (30.2) | 1940 (38.8) | 1031 (20.6) | 367 (7.3) | 127 (2.5) | 21 (0.4) | 1 (0.0) | 69.8% |
| 5-20% | 1757 (10.0) | 5489 (31.2) | 5152 (29.2) | 3216 (18.3) | 1568 (8.9) | 416 (2.4) | 22 (0.1) | 68.8% |
| 20-40% | 825 (3.2) | 4645 (18.3) | 7224 (28.4) | 6230 (24.5) | 4570 (18.0) | 1762 (6.9) | 138 (0.5) | 71.6% |
| 40-60% | 274 (1.0) | 2713 (9.8) | 6049 (21.8) | 7245 (26.1) | 7109 (25.6) | 3803 (13.7) | 547 (2.0) | 73.9% |
| 60-80% | 86 (0.3) | 1209 (4.1) | 3913 (13.4) | 6541 (22.3) | 8917 (30.5) | 7067 (24.1) | 1548 (5.3) | 69.5% |
| 80-95% | 17 (0.1) | 312 (1.3) | 1381 (5.8) | 3478 (14.5) | 6648 (27.8) | 8541 (35.7) | 3538 (14.8) | 64.3% |
| ≥ 95% | 0 (0.0) | 29 (0.3) | 115 (1.3) | 445 (5.1) | 1377 (15.8) | 3358 (38.6) | 3379 (38.8) | 61.2% |

Supplementary Table 12: Cross-classification of predicted risk of dementia among participants who experienced the outcome, according to the percentiles of each PRS. Initial score is [PRS-A](https://doi.org/10.1038/s41467-020-18534-1), updated score is [PRS-B](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438688/). 4,460 of 335,689 individuals (1.3%) experienced the outcome. Row %s shown, and may not add up to 100 due to rounding. Categorical NRI (95% CI): 0.033 (0.009, 0.057).

| Percentiles of PRS A | Percentiles of PRS B | % reclassified |
| --- | --- | --- |
| < 5% | 5-20% | 20-40% | 40-60% | 60-80% | 80-95% | ≥ 95% |
| < 5% | 74 (44.8) | 58 (35.2) | 25 (15.2) | 6 (3.6) | 2 (1.2) | 0 (0.0) | 0 (0.0) | 55.2% |
| 5-20% | 49 (9.1) | 204 (38.0) | 148 (27.6) | 91 (16.9) | 29 (5.4) | 15 (2.8) | 1 (0.2) | 62.0% |
| 20-40% | 11 (1.4) | 150 (19.4) | 267 (34.5) | 196 (25.4) | 107 (13.8) | 39 (5.0) | 3 (0.4) | 65.5% |
| 40-60% | 8 (0.9) | 65 (7.4) | 238 (27.2) | 241 (27.6) | 222 (25.4) | 90 (10.3) | 10 (1.1) | 72.4% |
| 60-80% | 1 (0.1) | 23 (2.4) | 96 (9.9) | 209 (21.6) | 328 (33.9) | 245 (25.3) | 66 (6.8) | 66.1% |
| 80-95% | 0 (0.0) | 6 (0.7) | 24 (2.9) | 101 (12.1) | 223 (26.7) | 350 (41.9) | 132 (15.8) | 58.1% |
| ≥ 95% | 0 (0.0) | 0 (0.0) | 1 (0.3) | 4 (1.3) | 38 (12.4) | 133 (43.3) | 131 (42.7) | 57.3% |

# ICD codes for disease ascertainment

Supplementary Table 13: ICD and OPCS codes for breast cancer outcome and exclusions. Individuals with prior breast cancer, carcinoma in situ or mastectomy were excluded. Breast cancer outcomes were identified from cancer registry, hospital episode statistics and death registry.

|  |  |  |
| --- | --- | --- |
| Breast cancer | Breast carcinoma in situ | Mastectomy |
| ICD-10 | **ICD-9** | **ICD-10** | **OPCS-4** |
| C50.0 | 1740 | D05.0 | B27.1 |
| C50.1 | 1741 | D05.1 | B27.2 |
| C50.2 | 1742 | D05.7 | B27.3 |
| C50.3 | 1743 | D05.9 | B27.4 |
| C50.4 | 1744 |  | B27.5 |
| C50.5 | 1745 |  | B27.6 |
| C50.6 | 1746 |  | B27.8 |
| C50.8 | 1748 |  | B27.9 |
| C50.9 | 1749 |  | B28.1 |
|  |  |  | B28.2 |
|  |  |  | B28.3 |
|  |  |  | B28.4 |
|  |  |  | B28.6 |

Supplementary Table 14: ICD codes for hypertension exclusions. Individuals with prior major adverse cardiovascular events (MACE) were excluded; MACE was identified from hospital episode statistics and UK Biobank baseline interview and touchscreen questionnaire answers (UK Biobank Data Fields [20002](https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=20002), [20004](https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=20004) and [6150](https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=6150))

| **MACE** |
| --- |
| **Hospital Episode Statistics** | **Verbal Interview** |
| **ICD-10** | **ICD-9** | **OPCS-4** | **Non-cancer illness** | **Operation** |
| I20.0 | 4109 | K40.1 | 1075 | 1070 |
| I21.0 | 4119 | K40.2 | 1081 | 1095 |
| I21.1 | 4129 | K40.3 | 1082 | 1105 |
| I21.2 | 4309 | K40.4 | 1086 | 1109 |
| I21.3 | 4319 | K40.8 | 1491 | 1523 |
| I21.4 | 4330 | K40.9 | 1583 |  |
| I21.9 | 4331 | K41.1 |   |   |
| I21.X | 4332 | K41.2 |  |  |
| I22.0 | 4333 | K41.3 |   |   |
| I22.1 | 4338 | K41.4 |  |  |
| I22.8 | 4339 | K41.8 |   |   |
| I22.9 | 4340 | K41.9 |  |  |
| I23.0 | 4341 | K42.1 |   |   |
| I23.1 | 4349 | K42.2 |  |  |
| I23.2 | 4359 | K42.3 |   |   |
| I23.3 | 4369 | K42.4 |  |  |
| I23.4 |   | K42.8 |   |   |
| I23.5 |  | K42.9 |  |  |
| I23.6 |   | K43.1 |   |   |
| I23.8 |  | K43.2 |  |  |
| I25.2 |   | K43.3 |   |   |
| I25.6 |  | K43.4 |  |  |
| I60.0 |   | K43.8 |   |   |
| I60.1 |  | K43.9 |  |  |
| I60.2 |   | K44.1 |   |   |
| I60.3 |  | K44.2 |  |  |
| I60.4 |   | K44.8 |   |   |
| I60.5 |  | K44.9 |  |  |
| I60.6 |   | K45.1 |   |   |
| I60.7 |  | K45.2 |  |  |
| I60.8 |   | K45.3 |   |   |
| I60.9 |  | K45.4 |  |  |
| I61.0 |   | K45.5 |   |   |
| I61.1 |  | K45.6 |  |  |
| I61.2 |   | K45.8 |   |   |
| I61.3 |  | K45.9 |  |  |
| I61.4 |   | K46.1 |   |   |
| I61.5 |  | K46.2 |  |  |
| I61.6 |   | K46.3 |   |   |
| I61.8 |  | K46.4 |  |  |
| I61.9 |   | K46.5 |   |   |
| I63.0 |  | K46.8 |  |  |
| I63.1 |   | K46.9 |   |   |
| I63.2 |  | K47.1 |  |  |
| I63.3 |   | K48.3 |   |   |
| I63.4 |  | K49.1 |  |  |
| I63.5 |   | K49.2 |   |   |
| I63.6 |  | K49.3 |  |  |
| I63.8 |   | K49.4 |   |   |
| I63.9 |  | K49.8 |  |  |
| I64.4 |   | K49.9 |   |   |
| G45.0 |  | K50.1 |  |  |
| G45.1 |   | K50.2 |   |   |
| G45.2 |  | K50.3 |  |  |
| G45.3 |   | K50.4 |   |   |
| G45.4 |  | K50.8 |  |  |
| G45.8 |   | K50.9 |   |   |
| G45.9 |  | K75.1 |  |  |
| G46.0 |   | K75.2 |   |   |
| G46.1 |  | K75.3 |  |  |
| G46.2 |   | K75.4 |   |   |
| G46.3 |  | K75.8 |  |  |
| G46.4 |   | K75.9 |   |   |
| G46.5 |  | L29.1 |  |  |
| G46.6 |   | L29.2 |   |   |
| G46.7 |  | L29.3 |  |  |
| G46.8 |   | L29.4 |   |   |
|  |  | L29.5 |  |  |
|   |   | L29.6 |   |   |
|  |  | L29.7 |  |  |
|   |   | L30.3 |   |   |
|  |  | L31.1 |  |  |
|   |   | L31.4 |   |   |
|  |  | L34.3 |  |  |
|   |   | L35.3 |   |   |
|   |   | L35.4 |   |   |

Supplementary Table 15: ICD codes for Dementia outcome and exclusions. Individuals with prior dementia were excluded. Dementia/Alzheimer’s disease outcomes were identified from hospital episode statistics and death registry.

|  |
| --- |
| Dementia |
| ICD-10 | **ICD-9** |
| A81.0 | 2902 |
| I67.3 | 2903 |
| F00.0 | 2904 |
| F00.1 | 2912 |
| F00.2 | 2941 |
| F00.9 | 3310 |
| F01.0 | 3311 |
| F01.1 | 3312 |
| F01.2 | 3315 |
| F01.3 |  |
| F01.8 |  |
| F01.9 |  |
| F02.0 |  |
| F02.1 |  |
| F02.2 |  |
| F02.3 |  |
| F02.4 |  |
| F02.8 |  |
| F03 |  |
| F05.1 |  |
| F10.6 |  |
| G30.0 |  |
| G30.1 |  |
| G30.8 |  |
| G30.9 |  |
| G31.1 |  |
| G31.8 |  |